TEK and neoplasm: As mentioned previously, REGN910 (an anti‐Ang2 antibody) was reported to be as efficacious as REGN1376 (an anti‐Tie2 antibody, that blocks both Ang1 and Ang2 binding) in six out of seven preclinical tumor models (Adler et al,2014).